The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Modes of resistance to anti-angiogenic therapy
Open accessAbstract
Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers. However, in both preclinical and clinical settings, the benefits are at best transitory and are followed by a restoration of tumour growth and progression. Emerging data support a proposition that two modes of unconventional resistance underlie such results: evasive resistance, an adaptation to circumvent the specific angiogenic blockade; and intrinsic or pre-existing indifference. Multiple mechanisms can be invoked in different tumour contexts to manifest both evasive and intrinsic resistance, motivating assessment of their prevalence and importance and in turn the design of pharmacological strategies that confer enduring anti-angiogenic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This dual blockade approach can provide tumour control in some preclinical models, although the degree of benefit and the underlying mechanism of action seem to be context-dependent31,32,80,89.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [80]
Experimental — accuracy not yet measuredIn the citing paper
“Drug resistance in cancer can be cell-intrinsic (Poulikakos and Rosen, 2011) or a combination of host and tumor mediated pathways (Bergers and Hanahan, 2008; Ebos et al., 2009).”
From A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012) · cites this paper as Bergers and Hanahan, 2008
In the citing paper
“Several cellular and molecular mechanisms of escape from antiangiogenic therapies have been postulated and investigated, including activation of alternative angiogenic pathways, recruitment of proangiogenic myeloid cells, increased pericyte cell coverage of tumour blood vessels, increased tumour cell invasion, and alternative modes of vessel recruitment7,9,80”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Self-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“Endothelial and pericyte progenitors differentiate into endothelial cells, which form the inner lining of blood vessel walls, or pericytes, the cells that envelop blood vessels, respectivel”
BackgroundPatterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Self-citationTargeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The HIF regulatory network also holds promise as a target, given its global effects on angiogenesis, invasion and stress-adaptive cell physiolog”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,551
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1256 · Cited by 3,414 · cited 1×
“By contrast, pro-angiogenic monocytes, such as tumour-associated macrophage”
BackgroundVEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K. D., Wang, M., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T. N., Cella, D. F., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,104 · cited 1×
“aspx?CdrID=39762">paclitaxel extended progression-free survival (but not overall survival”
BackgroundProgenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600 · cited 1×
“Evidence that low oxygen tension triggers the recruitment of BMDCs stems from observations in experimentally induced ischaemic tissue, wherein endothelial progenitors and other CXCR4 + BMDCs are recruited, in part through increases in HIF1α and its downstream effectors SDF1α (a CXCR4 ligand) and VEGF itsel”
Background
Research works printed but not linked: 1
- Berger, M. S. & Wilson, C. B. The Gliomas (W.B. Saunders, Philadelphia, 1999).
Cited by
Sorted by citations
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
“…where potent angiogenesis inhibitors succeed in suppressing this hallmark capability, tumors adapt and shift from a dependence upon continuing angiogenesis to heightening the activity of another instead—invasiveness and metastasis (Azam et al., 2010: Ebos et al., 2009; Bergers and Hanahan, 2008).”
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
“Aberrant FGF signalling promotes tumour angiogenesis and mediates the escape of tumour vascularization from VEGF- or epidermal growth factor receptor (EGFR)-inhibitor treatmen”
BackgroundWen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,890
“Increasing evidence suggests that anti-VEGF therapy may increase the tendency of tumor cells to co-opt existing blood vessels, resulting in an invasive nonenhancing phenotype.(52-54) Unlike the Macdonald Criteria, which do not take into account progressive nonenhancing disease, the new response assessment will conside…”
BackgroundMicroenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
“The translational promise of this first targeted therapy against the tumour microenvironment, however, is somewhat tempered by emerging instances of resistance to anti-angiogenic therap”
BackgroundBasic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
“…adoption of a quiescent endothelial phalanx phenotype, basement membrane deposition, pericyte coverage, and branch regression. patients show benefit as tumors evolve mechanisms of resistance or are refractory towardVEGF (receptor) inhibitors (Bergers and Hanahan, 2008; Crawford and Ferrara, 2009a).”
InfluentialVEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“Preclinical studies have implicated the release of hematopoietic growth factors from tumor or host cells and the resulting tumor infiltration of myeloid and other inflammatory cell types in the induction of VEGF-independent angiogenesis and escape (Bergers and Hanahan, 2008; De Palma et al., 2017; Shojaei et al., 2007…”
BackgroundHsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,426
Pàez‐Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,373
“Notably, like most systemic therapies, these drugs have not produced enduring efficacy in terms of either tumor shrinkage or dormancy (stable disease) or long-term survival; rather, the common result is delayed time to progression following a period of clinical benefit, which is suggestive of an emergent resistance to…”
InfluentialSelf-citationLenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M. J., Tahara, M., Wirth, L. J., Robinson, B. G., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K. L., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,152
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 2,149
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Pre-metastatic niches: organ-specific homes for metastases
Peinado, H., Zhang, H., Matei, I. R., Costa-Silva, B., Hoshino, A., Rodrigues, G., Psaila, B., Kaplan, R. N., Bromberg, J. F., Kang, Y., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.6 · Cited by 1,889
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,762
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz‐Muñoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,739
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,740
“In addition, some preclinical studies show that blocking VEGF may promote metastasi”
BackgroundThe role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
“The mechanisms underlying the effect of such cells on tumour resistance to other anti-angiogenic therapies are described in further detail by Bergers and Hanahan in this issu”
BackgroundSignal Transduction by Vascular Endothelial Growth Factor ReceptorsPreprint
Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson, L. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1042/bj20110301 · Cited by 1,710
“Finally, the recent challenges in the application of VEGF-targeted therapies with resistance, rescue (Bergers and Hanahan 2008), and, at least in mouse models, increased invasion and metastasis (Ebos et al. 2009; Paez-Ribes et al. 2009) have shown that we need to learn more about how blood vessels…”
BackgroundVEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Viallard, C., & Larrivée, B. (2017) · Angiogenesis · doi:10.1007/s10456-017-9562-9 · Cited by 1,476
“Finally, the benefits of anti-VEGF are transitory and are followed by a resumption of tumor growth due to adaptive resistance or preexisting non-responsiveness [115].”
BackgroundYakes, F. M., Chen, J., Tan, J., Yamaguchi, T., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,350
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z., Chen, H., Zheng, L., Sun, L., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,486
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
“Other evasive pathways emerging from preclinical and clinical studies include Ang2 and cMET.(16,89,90,97,171-173) These biomarkers and pathways need to be tested prospectively.”
BackgroundWilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355
“Indeed, adaptive responses by the tumor and its vasculature to anti-VEGF therapy have been hypothesized.(41) Such responses include hypoxia-mediated induction of other proangiogenic factors, such as Ang1 and FGFs,(42,43) or upregulation of PDGF-C expression in tumor-associated fibroblasts.”
BackgroundHypoxia-Induced Angiogenesis: Good and Evil
Krock, B. L., Skuli, N., & Simon, M. C. (2011) · Genes & Cancer · doi:10.1177/1947601911423654 · Cited by 1,236
“Tumors often evade single-agent antiangiogenic therapies through the selective activation of alternate pro-angiogenic pathways.(95) Consequently, simultaneous blockade of multiple pro-angiogenic pathways is more effective than single-agent anti-angiogenics.”
BackgroundBennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Hallmarks of cancer: Interactions with the tumor stroma
Pietras, K., & Östman, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.045 · Cited by 1,187
“Given the proposed role for pericytes in the development of resistance to anti-angiogenic therapy [55], a better understanding of pericyte subpopulations may enable the prediction of response in patients to this new class of agents.”
BackgroundA CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085
“Drug resistance in cancer can be cell-intrinsic (Poulikakos and Rosen, 2011) or a combination of host and tumor mediated pathways (Bergers and Hanahan, 2008; Ebos et al., 2009).”
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
“However, this seems increasingly unlikely, as it is now established that therapeutic interception of VEGF is counteracted by the compensatory induction of other proangiogenic factors, some of which are involved in monocyte/myeloid cell chemoattraction (Bergers and Hanahan, 2008; Ferrara, 2010).”
BackgroundDefining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050
Langley, R. R., & Fidler, I. J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26031 · Cited by 1,002
Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future
Arvizo, R. R., Bhattacharyya, S., Kudgus, R. A., Giri, K., Bhattacharya, R., & Mukherjee, P. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15355f · Cited by 886
Antiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R. S., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 860
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Self-citationMazzone, M., Dettori, D., de Oliveira, R. L., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.-M., Lanahan, A. A., Pollard, P. J., de Almodóvar, C. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.020 · Cited by 828
“Nonetheless, current antiangiogenic agents induce tumor hypoxia by pruning vessels or forming hypoperfused vessels, which can stimulate angiogenesis and limit their success (Bergers and Hanahan, 2008).”
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Kioi, M., Vogel, H. S., Schultz, G. M., Hoffman, R. M., Harsh, G. R., & Brown, J. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40283 · Cited by 778
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 758
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
Lohela, M. K., Bry, M., Tammela, T., & Alitalo, K. K. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.012 · Cited by 752
Curcumin: An Anti-Inflammatory Molecule from a Curry Spice on the Path to Cancer Treatment
Basnet, P., & Škalko‐Basnet, N. (2011) · Molecules · doi:10.3390/molecules16064567 · Cited by 750
“This concept is exemplified by recent discoveries [165-167].”
BackgroundRolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695
“Traditional antiangiogenic ''vessel pruning'' agents can aggravate tumor hypoxia and worsen malignancy (Bergers and Hanahan, 2008).”
BackgroundAntiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
“Numerous mechanisms of resistance to antiangiogenic therapy have been propose”
BackgroundAntiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., Clouthier, S. G., & Wicha, M. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018866109 · Cited by 663
“Although these agents typically produce inhibition of primary tumor growth, lasting responses are rare, with only a moderate increase in progression-free survival and little benefit in overall survival (3).”
BackgroundAnti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 680
“Angiogenesis is known to be an essential hallmark for solid tumors, but other modes of tumor new vessel formation exist and have been linked with intrinsic or adaptive resistance to anti-angiogenic treatment [126].”
Metronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 666
“Nevertheless, both intrinsic and acquired resistance to anti-angiogenic drugs are emerging as clinically relevant issues”
BackgroundMazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
“However, antiangiogenic treatments targeting the VEGF pathway rarely induce durable tumor responses, both in mice and patients with cancer (Bergers and Hanahan, 2008), and may also favor metastasis in selected tumor models (Ebos et al., 2009; Paez-Ribes et al., 2009).”
BackgroundInfluentialIn vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., et al. (2014) · Nature · doi:10.1038/nature13902 · Cited by 640
The Role of Adiponectin in Cancer: A Review of Current Evidence
Dalamaga, Μ., Diakopoulos, K. N., & Mantzoros, C. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1015 · Cited by 653
The angiogenic switch in carcinogenesis
Baeriswyl, V., & Christofori, G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.003 · Cited by 674
“unitinib and sorafenib, two TKI mainly targeting VEGFR-2 have een approved for the treatment of renal carcinoma, gastrointestial stromal tumors and hepatocellular carcinomas [59].”
BackgroundCrawford, Y., Kasman, I. M., Yu, L., Zhong, C., Wu, X., Modrusan, Z. D., Kaminker, J. S., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 635
“Other studies investigating tumor resistance/refractoriness to antiangiogenic therapies with VEGF blockers have identified additional potential mechanisms, including expression of alternative angiogenic factors (Bergers and Hanahan, 2008; Fischer et al., 2007), selection of hypoxia-resistant tumor cells (Yu et al.”
BackgroundGold Nanoparticles in Cancer Treatment
Sztandera, K., Gorzkiewicz, M., & Klajnert‐Maculewicz, B. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00810 · Cited by 608
Consensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska, P. M., Alitalo, K. K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., B, J. R. V. B., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 619
Self-citationLlovet, J. M., Decaens, T., Raoul, J., Boucher, É., Kudo, M., Chang, C., Kang, Y., Assénat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 595
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 598
Monocyte heterogeneity and functions in cancer
Olingy, C. E., Dinh, H. Q., & Hedrick, C. C. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ri0818-311r · Cited by 598
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582
“The lack of durable antitumoral responses after VEGFA inhibition mirrors that of other targeted drugs and can be attributed, at least in part, to compensatory proangiogenic signaling, either induced or preexisting in tumors (4, 5).”
BackgroundPark, J. E., Tan, H. S., Datta, A., Lai, R. C., Zhang, H., Meng, W., Lim, S. K., & Sze, S. K. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900381-mcp200 · Cited by 582
“For example, prolonged antiVEGF treatment on tumors is known to select for the tumor cells that recruit alternative angiogenesis signaling pathways involving fibroblast growth factor, platelet-derived growth factor (PDGF), and angiopoietins (5).”
BackgroundEelen, G., de Zeeuw, P., Treps, L., Harjes, U., Wong, B. W., & Carmeliet, P. (2017) · Physiological Reviews · doi:10.1152/physrev.00001.2017 · Cited by 614
Resistance to targeted therapy in renal-cell carcinoma
Rini, B. I., & Atkins, M. B. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70240-2 · Cited by 569
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2524 · Cited by 582
“Second, despite disease stabilization and an increase in the proportion of progression-free patients or the overall survival of patients with cancer treated with anti-VEGF therapies, tumours eventually escape and relapse, such that anti-VEGF therapies currently have an absolute gain in duration of survival in terms of…”
BackgroundKurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 566
“Despite initial responsiveness, however, the beneficial effects of bevacizumab are transient, and GBM inevitably progress during anti-VEGF treatment by adapting and utilizing alternative pathways to sustain tumor growth, all while VEGF signaling remains inhibited (Bergers and Hanahan, 2008).”
Self-citationGlioblastoma: defining tumor niches
Hambardzumyan, D., & Bergers, G. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.009 · Cited by 522
“Hypoxia promotes EMT and stem-like properties of tumor cells, upregulates pro-angiogenic and invasive factors, and drives the infiltration and polarization of angiogenic and immunesuppressive myeloid cells (reviewed in [97, 98]).”
BackgroundSelf-citationAdrenergic nerves activate an angio-metabolic switch in prostate cancer
Zahalka, A. H., Arnal-Estapé, A., Maryanovich, M., Nakahara, F., Cruz, C. D., Finley, L. W. S., & Frenette, P. S. (2017) · Science · doi:10.1126/science.aah5072 · Cited by 548
de Gramont, A., Van Cutsem, E., Schmoll, H.-J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70509-0 · Cited by 529
Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis
Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., & Acker‐Palmer, A. (2010) · Nature · doi:10.1038/nature08995 · Cited by 551
The tumor microenvironment and its contribution to tumor evolution toward metastasis
Lorusso, G., & Rüegg, C. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0530-8 · Cited by 540
“Furthermore, recent experimental evidence indicates that tumors can develop resistance to antiangiogenic therapy (Bergers and Hanahan 2008).”
BackgroundA history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
Adipocyte and lipid metabolism in cancer drug resistance
Cao, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127201 · Cited by 531
“Intrinsic and acquired AAD resistance often occurs in cancer patients and considerably hampers therapeutic efficacy (164, 165).”
BackgroundPharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 544
“These function to promote vascular growth by producing cytokines, growth factors and proteases that promote vascular growth and development [Bergers and Hanahan, 2008].”
BackgroundOvercoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 544
“However, antiangiogenic agents are still deficient and usually stimulate cancer to develop stress resistance states.(294) Accordingly, the identification of more effective drugs with antiangiogenic activity by drug repurposing is important for improving cancer therapy.”
BackgroundTransdifferentiation of glioblastoma cells into vascular endothelial cells
Soda, Y., Marumoto, T., Friedmann‐Morvinski, D., Soda, M., Liu, F., Michiue, H., Pastorino, S., Yang, M., Hoffman, R. M., Kesari, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016030108 · Cited by 541
“Mechanisms proposed to explain resistance to anti-VEGF therapy include activation of other proangiogenic signaling pathways, recruitment of bone marrow (BM)-derived myeloid cells that protect and nurture vascular cells, protection of blood vessels by increased pericyte coverage, and increased tumor invasion (4, 5).”
BackgroundAnand, S., Majeti, B. K., Acevedo, L. M., Murphy, E. A., Mukthavaram, R., Scheppke, L., Huang, M., Shields, D. J., Lindquist, J. N., Lapinski, P. E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2186 · Cited by 517
“There is emerging evidence that some of the current antiangiogenic therapies, which target single pathways such as the VEGFR pathway, can lead to the development of 'evasive resistance' in tumors through the upregulation of alternative growth factor”
BackgroundYamamoto, Y., Matsui, J., Matsushima, T., Obaishi, H., Miyazaki, K., Nakamura, K., Tohyama, O., Semba, T., Yamaguchi, A., Hoshi, S., et al. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-18 · Cited by 507
“There are accumulating evidences that tumor vasculature evaluated by MVD and % of pericyte coverage has an impact on disease prognosis and/or acquired resistance to antiangiogenesis therapy in cancer patients [4,23].”
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2009) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 526
“A small fraction of patients fails to show even initial clinical benefit [ 12 ].”
BackgroundCroci, D. O., Cerliani, J. P., Dalotto‐Moreno, T., Méndez‐Huergo, S. P., Mascanfroni, I. D., Dergan‐Dylon, S., Toscano, M. A., Caramelo, J. J., García-Vallejo, J. J., Ouyang, J., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.043 · Cited by 514
“Stimulation of ECs with FGF2 or a combination of IL-10 and TGF-b1 led to reduction of SNA-reactive glyco-epitopes, as compared to resting, IL-17- or IFN-g-treated ECs (Figures 1B and 1C), suggesting that pro- or anti-inflammatory signals may either mask or unmask Gal1-specific binding sites.”
InfluentialMolecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K., & Heymach, J. V. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1366 · Cited by 535
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine
Favier, J., Amar, L., & Gimenez‐Roqueplo, A. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.188 · Cited by 484
Hu, Y., DeLay, M., Jahangiri, A., Molinaro, A. M., Rose, S. D., Carbonell, W. S., & Aghi, M. K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3831 · Cited by 491
“this efficacy is often transient with acquired resistance to antiangiogenic therapy common (32).”
BackgroundVEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Saharinen, P., Eklund, L., Pulkki, K. H., Bono, P., & Alitalo, K. K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.015 · Cited by 489
Targeting the ANGPT–TIE2 pathway in malignancy
Huang, H., Bhat, A., Woodnutt, G., & Lappe, R. W. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2894 · Cited by 479
“However, they result in only transient responses in the clinic, primarily owing to drug resistanc”
BackgroundBroad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El‐Rayes, B. F., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 479
“The switch depends on increased production of ne or more positive regulators of angiogenesis, such as vascuar endothelial growth factor (VEGF), fibroblast growth factor-2 FGF-2), interleukin-8 (IL-8), placental growth factor (PlGF), transorming growth factor-beta (TGFbeta), platelet derived growth actor (PDGF), angiop…”
BackgroundInfluentialAn interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445
Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S., & Reynolds, A. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0181-9 · Cited by 457
Taylor, M. H., Lee, C., Makker, V., Rasco, D. W., Dutcus, C. E., Wu, J., Stepan, D. E., Shumaker, R. C., & Motzer, R. J. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01598 · Cited by 438
“Unknown 0 (0) 0 (0) 2 (9) 1 (5) 2 (10) 4 (20) ORR 21 (70) 12 (52) 10 (46) 10 (48) 7 (33) 5 (25)”
InfluentialEl‐Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El‐Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 436
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma
Ahir, B. K., Engelhard, H. H., & Lakka, S. S. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01892-8 · Cited by 454
Qin, X., Guo, H.-Y., Wang, X.-N., Zhu, X.-Q., Yan, M., Wang, X., Xu, Q., Shi, J.-B., Lu, E., Chen, W., et al. (2019) · Genome Biology · doi:10.1186/s13059-018-1604-0 · Cited by 386
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Deryugina, E. I., & Quigley, J. P. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.04.004 · Cited by 435
“…lack of substantial benefits of anti-VEGF therapies attributed to resistance, adaptation and normalization of tumor vasculature in cancer patients (Bergers and Hanahan, 2008; Claes et al., 2008; Goel et al., 2011; Mancuso et al., 2006; Shojaei et al., 2007; Welti et al., 2013), has clearly…”
BackgroundDudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424
“…angiogenesis response in tumors, if there are any unique properties in VW-EPCs that could be exploited as an antiangiogenesis strategy, or if VW-EPCs might mediate vascular rebound often observed following antiangiogenic therapies in the clinic (Bergers and Hanahan 2008; Ellis and Hicklin 2008).”
BackgroundInterleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Huang, D., Ding, Y., Zhou, M., Rini, B. I., Petillo, D., Qian, C.-N., Kahnoski, R. J., Futreal, P. A., Furge, K. A., & Teh, B. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3965 · Cited by 417
Sennino, B., Ishiguro‐Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V. J., Tabruyn, S. P., You, W., Chapman, H. A., Christensen, J. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0240 · Cited by 404
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., Hajj, H. E., Khalifeh, I. M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 430
“As a result of protecting ECs from anti-angiogenic agents, pericytes were implicated in clinical resistance to VEGFR inhibitors (249).”
BackgroundSignaling by members of the TGF-β family in vascular morphogenesis and disease
Pardali, E., Goumans, M., & ten Dijke, P. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.06.006 · Cited by 402
Huinen, Z. R., Huijbers, E. J. M., B, J. R. V. B., Nowak-Sliwinska, P. M., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 415
Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
Loges, S., Mazzone, M., Hohensinner, P. J., & Carmeliet, P. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.007 · Cited by 400
“In addition, tumors recruit other vascular supply mechanisms, such as mobilization of angiocompetent bone marrow-derived cells (Grunewald et al., 2006) or co-option of existing vasculature, that are not always inhibited by VEGF-targeted therapy (Bergers and Hanahan, 2008).”
BackgroundCombination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 376
“mechanisms, which include changes in both tumor cells and tumor-associated host stromal cells (150).”
BackgroundCancer systems biology: a network modeling perspective
Kreeger, P. K., & Lauffenburger, D. A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp261 · Cited by 382
Metadata
- Authors
- Bergers, G., & Hanahan, D.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Nature Reviews Cancer
- Published
- 2008-08
- Volume
- 8
- Issue
- 8
- Pages
- 592-603
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC2874834
- OpenAlex
- W2017322644
- Cited by
- 2,953
- References
- 101
- Citations by year
- 2026: 70 · 2025: 77 · 2024: 97 · 2023: 130 · 2022: 95 · 2021: 172 · 2020: 133 · 2019: 152 · 2018: 148 · 2017: 202 · 2016: 217 · 2015: 228 · 2014: 241 · 2013: 248 · 2012: 215
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA099948)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- anti-angiogenic therapy, drug resistance, vascular endothelial growth factor, VEGF signaling, tumor angiogenesis, intrinsic resistance, combination therapy
- MeSH terms
- Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
